Nectar Lifesciences Ltd

Lokesh Machines Ltd, Rhetan TMT Ltd, Vibhor Steel Tubes Ltd and Dreamfolks Services Ltd are among the other losers in the BSE's 'B' group today, 09 July 2025.Nectar Lifescience Ltd tumbled 9.93% to Rs 16.69 at 14:31 IST.The stock was the biggest loser in the BSE's 'B' group.On the BSE, 28.52 lakh shares were traded on the counter so far as against the average daily volumes of 2.2 lakh shares in the past one month.Lokesh Machines Ltd crashed 7.85% to Rs 218.85. The stock was the second biggest loser in 'B' group.On the BSE, 42757 shares were traded on the counter so far as against the average daily volumes of 12459 shares in the past one month.Rhetan TMT Ltd lost 7.75% to Rs 17.49. The stock was the third biggest loser in 'B' group.On the BSE, 21.83 lakh shares were traded on the counter so far as against the average daily volumes of 6.83 lakh shares in the past one month.Vibhor Steel Tubes Ltd slipped 5.35% to Rs 182.3. The stock was the fourth biggest loser in 'B' group.On the BSE, 6454 shares were traded on the counter so far as against the average daily volumes of 9926 shares in the past one month.Dreamfolks Services Ltd dropped 5.29% to Rs 167.55. The stock was the fifth biggest loser in 'B' group.On the BSE, 3.18 lakh shares were traded on the counter so far as against the average daily volumes of 1.15 lakh shares in the past one month.Powered by Capital Market - Live

Nectar Lifescience announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 4 August 2025.Powered by Capital Market - Live

Rajdarshan Industries Ltd, Sharda Motor Industries Ltd, PC Jeweller Ltd and PVP Ventures Ltd are among the other losers in the BSE's 'B' group today, 08 July 2025.Nectar Lifescience Ltd tumbled 19.99% to Rs 18.53 at 14:31 IST.The stock was the biggest loser in the BSE's 'B' group.On the BSE, 22 lakh shares were traded on the counter so far as against the average daily volumes of 1.27 lakh shares in the past one month.Rajdarshan Industries Ltd crashed 8.51% to Rs 52.6. The stock was the second biggest loser in 'B' group.On the BSE, 2204 shares were traded on the counter so far as against the average daily volumes of 1544 shares in the past one month.Sharda Motor Industries Ltd lost 7.27% to Rs 1132.25. The stock was the third biggest loser in 'B' group.On the BSE, 25991 shares were traded on the counter so far as against the average daily volumes of 8659 shares in the past one month.PC Jeweller Ltd plummeted 6.78% to Rs 17.45. The stock was the fourth biggest loser in 'B' group.On the BSE, 356.88 lakh shares were traded on the counter so far as against the average daily volumes of 91.41 lakh shares in the past one month.PVP Ventures Ltd fell 6.06% to Rs 20.91. The stock was the fifth biggest loser in 'B' group.On the BSE, 1.21 lakh shares were traded on the counter so far as against the average daily volumes of 26062 shares in the past one month.Powered by Capital Market - Live

The deal, executed on a slump sale basis, includes the manufacture, distribution, and marketing of APIs (active pharmaceutical ingredients) and formulations. As part of the broader restructuring, Nectar has also signed an asset purchase agreement to divest its menthol business assets to Ceph Lifesciences for an additional Rs 20 crore. The transaction, expected to be completed by 20 September 2025, is subject to shareholder approval at an extraordinary general meeting scheduled for August 4. According to the company, this sale marks a significant pivot toward becoming a more focused and innovation-driven enterprise. Proceeds from the deal will be used to repay existing debt, invest in emerging opportunities, potentially reward shareholders and fund future growth initiatives. The buyer, Ceph Lifesciences, is a non-promoter entity with no impact on Nectar's existing shareholding pattern post-transaction. Sanjiv Goyal, promoter and chairman of Nectar Lifesciences, commented: This transaction marks a significant milestone in Nectar Lifesciences' evolution. By divesting mature segments of our business, we are laying the foundation for a focused and agile organization geared towards innovation and long-term value creation. We thank our stakeholders for their continued trust and support as we embark on this next chapter. Nectar Lifesciences is a pharmaceutical company focused on research-driven innovation, manufacturing, and global distribution. The company will announce Q4 results on 7 July 2025. On a consolidated basis, net profit of Nectar Lifescience soared 399.36% to Rs 7.84 crore while net sales rose 0.48% to Rs 454.33 crore in Q3 December 2024 over Q3 December 2023. Powered by Capital Market - Live

Nectar Lifescience will hold a meeting of the Board of Directors of the Company on 7 July 2025.Powered by Capital Market - Live

Nectar Lifescience will hold a meeting of the Board of Directors of the Company on 30 May 2025.Powered by Capital Market - Live

In a regulatory filing made after market hours yesterday, the company stated that its API manufacturing facility in Saidpura, Mohali, Punjab, underwent a joint inspection by the European Directorate for the Quality of Medicines & HealthCare (EDQM) and the Spanish Agency of Medicines and Medical Devices (AEMPS) to assess compliance with EuGMP standards. Following the inspection, seven observations including four critical, were noted. Nectar Lifesciences said that it is in the process of preparing a corrective action and preventive action (CAPA) report to address the observations. The company emphasized its commitment to quality and compliance with cGMP standards. The European regulator will conduct a re-inspection of the facility to verify the compliance and CAPA submitted which may lead to EuGMP approval. Nectar Lifesciences is a research-based pharmaceutical company, primarily engaged in manufacturing APIs and formulation. The company has four manufacturing facilities across Punjab and Himachal Pradesh. The company is into manufacturing Cephalosporin (oral and sterile) at its two units in Derabassi and Punjab. The company's consolidated net profit surged to Rs 7.84 crore in the quarter ended December 2024 as against Rs 1.57 crore during the previous quarter ended December 2023. Sales rose 0.48% to Rs 454.33 crore in Q3 FY25 as compared with Q3 FY24. Powered by Capital Market - Live

Net profit of Nectar Lifescience rose 399.36% to Rs 7.84 crore in the quarter ended December 2024 as against Rs 1.57 crore during the previous quarter ended December 2023. Sales rose 0.48% to Rs 454.33 crore in the quarter ended December 2024 as against Rs 452.16 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales454.33452.16 0 OPM %9.849.33 - PBDT28.1617.83 58 PBT12.552.46 410 NP7.841.57 399 Powered by Capital Market - Live

Nectar Lifescience will hold a meeting of the Board of Directors of the Company on 31 January 2025.Powered by Capital Market - Live

Net profit of Nectar Lifescience rose 449.02% to Rs 5.60 crore in the quarter ended September 2024 as against Rs 1.02 crore during the previous quarter ended September 2023. Sales rose 7.52% to Rs 427.88 crore in the quarter ended September 2024 as against Rs 397.96 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales427.88397.96 8 OPM %10.136.75 - PBDT24.2116.95 43 PBT8.671.64 429 NP5.601.02 449 Powered by Capital Market - Live